Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs.
The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF.
The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 15, 24 | -0.20 Increased by +67.74% | -0.19 Decreased by -7.12% |
| Aug 9, 24 | -0.18 Increased by +70.00% | -0.23 Increased by +20.00% |
| May 9, 24 | -0.19 Increased by +24.00% | -0.21 Increased by +9.52% |
| Mar 8, 24 | -0.53 Increased by +53.37% | -0.21 Decreased by -153.14% |
| Nov 14, 23 | -0.62 | -0.29 Decreased by -113.79% |
| Aug 10, 23 | -0.60 | -0.28 Decreased by -114.29% |
| May 11, 23 | -0.25 | -0.41 Increased by +39.02% |
| Mar 31, 23 | -1.14 | -0.82 Decreased by -39.02% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -33.98 M Decreased by -42.39% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -26.03 M Decreased by -11.83% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -26.04 M Decreased by -44.85% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.33 M Increased by +N/A% | -24.67 M Decreased by -107.76% | Decreased by -1.86 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -23.86 M Decreased by -71.27% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -23.28 M Decreased by -66.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -17.98 M Decreased by -37.41% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -11.88 M Decreased by -76.86 K% | Decreased by N/A% Decreased by N/A% |